Jos de Man

Head of Chemistry

Therapeutic Areas

Drug	Indication	Phase
CFON-026	B-cell malignancies (via BTK inhibition)	Pre-clinical
BAL0891	Oncology (via TTK/PLK1 inhibition)	Clinical (Phase not specified)